ReviewEuropean respiratory review : an official journal of the European Respiratory Society2017
Severe idiopathic pulmonary fibrosis: what can be done?
Review in European respiratory review : an official journal of the European Respiratory Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 38 citations in OpenAlex.
- Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies.Advances in therapy · 2023Trial
- Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.BMC pulmonary medicine · 2020Trial
- The impact of palliative care on quality of life, anxiety, and depression in idiopathic pulmonary fibrosis: a randomized controlled pilot study.Respiratory research · 2020Trial
- Prognostic significance of antifibrotic agents in idiopathic pulmonary fibrosis after initiation of long-term oxygen therapy.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024Article
- Review
- The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021Article
- Reference values for high attenuation areas on chest CT in a healthy, never-smoker, multi-ethnic sample: The MESA study.Respirology (Carlton, Vic.) · 2020Article
- Impact of COVID-19 outbreak in an Italian cohort of patients with systemic sclerosis.Therapeutic advances in musculoskeletal disease · 2020Article
- Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey.ERJ open research · 2019Article
- Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.European respiratory review : an official journal of the European Respiratory Society · 2019Review
- RNA sequencing of transplant-stage idiopathic pulmonary fibrosis lung reveals unique pathway regulation.ERJ open research · 2019Article
- Pulmonary rehabilitation improves survival in patients with idiopathic pulmonary fibrosis undergoing lung transplantation.Scientific reports · 2019Article
- Therapeutic effects of obeticholic acid (OCA) treatment in a bleomycin-induced pulmonary fibrosis rat model.Journal of endocrinological investigation · 2019Article
- Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study.Advances in therapy · 2019Article
- Tetraspanin 1 inhibits TNFα-induced apoptosis via NF-κB signaling pathway in alveolar epithelial cells.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2018Article
- Marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last two years of life.BMC pulmonary medicine · 2018Article
- Rare pulmonary diseases: a common fight.European respiratory review : an official journal of the European Respiratory Society · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary fibrosis (IPF) remains a challenging disease to manage. Two drugs are now available that can slow disease progression in patients with mild-to-moderate IPF. This means that early diagnosis is mandatory, because there are no proven effective therapies for severe IPF. This lack of proven therapies may be at least partially due to the fact that severe IPF patients are usually not enrolled in randomised, prospective, multicentre, international trials. Clinical observation experiences and preliminary results of long-term, open-label extensions of clinical trials suggest that both pirfenidone and nintedanib may also slow or decrease progression in patients with severe IPF. However, data are sparse and obtained from a relatively small number of patients. Lung transplantation should be taken into account early and discussed with patients, when indicated. Rehabilitative strategies are important and effective supportive therapies. The needs of patients with severe IPF are similar to those of patients with an advanced neoplastic disease. Palliative care and psychological support play an important role in the relief of symptoms of anxiety and depression. Accordingly, these therapeutic approaches should start early in IPF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.